GCTK · XBRL financial data
Glucotrack financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (GCTK's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Research and development | 1,532 | 1,810 | 1,967 | 4,704 | 9,499 | 9,813 |
| Selling, general and administrative | 415 | 139 | — | — | — | — |
| General and administrative | 1,185 | 2,091 | 2,465 | 2,278 | 4,655 | 6,277 |
| Total operating expenses | 3,132 | 4,040 | 4,432 | 7,104 | 14,547 | 16,090 |
| Operating income (loss) | 3,132 | (4,040) | (4,432) | (7,104) | (14,547) | (16,090) |
| Interest expense | — | — | — | — | 44 | — |
| Other income (expense) | 338 | (53) | (14) | — | 14 | 26 |
| Net income (loss) | 2,696 | (4,067) | (4,435) | (7,097) | (22,597) | (19,388) |
| Earnings per share, basic USD per share | (0.02) | 0.26 | 0.29 | 0.38 | 68.44 | 31.22 |
| Earnings per share, diluted USD per share | (0.02) | 0.26 | 0.29 | 0.38 | 68.44 | 31.22 |
| Weighted average shares, basic thousands of shares | 196,029 | 15,451 | 15,475 | 20,760 | 330 | 621 |
| Weighted average shares, diluted thousands of shares | 196,029 | — | 15,475 | 20,760 | 330 | 621 |
- † Share count changed about 1/13 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/13 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (GCTK's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 9,823 | 6,062 | 2,312 | 4,492 | 5,617 | 7,383 |
| Accounts receivable | 66 | — | — | — | — | — |
| Inventory | 284 | — | — | — | — | — |
| Total current assets | 10,229 | 6,105 | 2,379 | 4,868 | 5,768 | 7,667 |
| Property and equipment, net | 149 | 69 | 40 | 27 | 95 | 138 |
| Right-of-use asset | 166 | 40 | — | — | 59 | 33 |
| Total assets | 10,606 | 6,265 | 2,438 | 4,905 | 5,932 | 7,838 |
| Accounts payable | 869 | 631 | 672 | 839 | 992 | 1,317 |
| Accrued liabilities | 148 | 131 | 325 | — | — | — |
| Total current liabilities | 1,345 | 883 | 1,013 | 1,512 | 1,275 | 4,773 |
| Lease liability, non-current | 82 | 17 | — | — | 33 | 5 |
| Total liabilities | 1,624 | 1,110 | 1,208 | 1,708 | 18,932 | 5,010 |
| Accumulated deficit | (93,399) | (97,466) | (101,901) | (109,853) | (132,450) | (151,838) |
| Total stockholders' equity | 8,982 | 5,155 | 1,230 | 3,197 | (13,000) | 2,828 |
| Total liabilities and equity | 10,606 | 6,265 | 2,438 | 4,905 | 5,932 | 7,838 |
| Common shares outstanding (cover page) thousands of shares | 200,782 | 15,455 | 15,504 | 26,756 | 25,586 | 1,944 |
- † Share count changed about 1/13 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/13 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (GCTK's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | 2,696 | (4,067) | (4,435) | (7,097) | (22,597) | (19,388) |
| Stock-based compensation | 22 | 223 | 439 | 281 | 173 | 211 |
| Net cash from operating activities | (3,501) | (3,769) | (3,729) | (6,558) | (12,490) | (15,240) |
| Purchases of property and equipment | 53 | 5 | 1 | — | 104 | 96 |
| Net cash from investing activities | (53) | (1) | 1 | — | (104) | (96) |
| Proceeds from issuing common stock | 13,009 | — | — | — | — | — |
| Net cash from financing activities | 13,009 | — | — | 8,730 | 13,743 | 17,043 |
| Net change in cash | 9,409 | (3,772) | (3,782) | 2,171 | 1,125 | 1,756 |
- † Share count changed about 1/13 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/13 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Glucotrack | 1,124 | not reported | (3,616)* | 10.6M | 0.3 quarters | 10-QJun 30, 2026 |
| Aethlon Medical | 4,934 | not reported | (1,897) | 711,136 | 2.6 quarters | 10-QJun 30, 2026 |
| Family Office of America | 637 | 533 | 149* | 30.8M | — | 10-QJun 30, 2026 |
| Odyssey Health | 122 | not reported | (160)* | 110.2M | 0.8 quarters | 10-KJul 31, 2026 |
| Autonomix Medical | 3,460 | 0 | (3,544) | 971,043 | 1.0 quarters | 10-QJun 30, 2026 |
| Sonoma Pharmaceuticals | 5,338 | 6,406 | (649) | 4.8M | 8.2 quarters | 10-QJun 30, 2026 |
| Nuwellis | 3,922 | 1,969 | (3,175)* | 3.6M | 1.2 quarters | 10-QJun 30, 2026 |
| Adm Tronics Unlimited | 223 | not reported | (33) | 67.6M | 6.8 quarters | 10-QJun 30, 2026 |
| Bone Biologics | 6,088 | not reported | (532)* | 3.4M | 9.8 quarters | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.